Kite Pharma, Inc. (NASDAQ:KITE) closed its last session at $48.53 with the change of -6.85%. The market capitalization of the company is $2.38B with an average Volume of 836.07 thousand shares. The stock currently has its 52-Week High range of $89.84 and 52-week low range of $38.41. The Price to Book (P/B) ratio stands at 4.34. The stock traded total quantity of 4.98 million shares.
For the current Fiscal Quarter, 13 analysts have given an average earnings per share forecast of $-1.21. The Low Earnings per share estimate of the current Quarter is $-1.56 and High Estimate is set at $-0.9 according to these Analysts opinions. The Previous Year EPS of this Quarter is $-0.48.
According to 12 analysts, an average sales Estimate of the current Fiscal quarter is $4.86M. The lower sales estimate is $3.60M and higher sales estimate is $6.30M according to these Analysts thoughts.
The Company currently has Highest Price Target of $88 and Lowest Price Target of $58. It has Median Price Targets of $75. Mean price target is set at $73.92 after consensus analysis of 13 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month 6 analysts have assigned this stock as Strong Buy where 7 assigned Buy, 0 analysts believe it’s a Hold, 0 said Underperform and 0 assigned Sell rating.
PDL BioPharma, Inc. (NASDAQ:PDLI) ended its last trade at $3.28 with the move of +3.14%. The company has market value of $541.57M with the total traded volume of 1.31 million. The stock currently has its 52-Week top value of $6.63 and 52-week down value of $2.58. The price to book (P/B) ratio of the company is 0.71. Its previous closing price was recorded at $3.18.
For the current Fiscal Quarter, 2 analysts have given an Average earnings estimate of $0.08 per share. According to the Analysts, the Low Estimate Earnings of the current Quarter is $0.06 while High Estimate is $0.1. The Previous Year EPS of this Quarter is $0.47.
According to 2 analysts, an Average Revenue Estimate of the current Fiscal quarter is $33.46M. According to them, the Low Revenue estimate is $27.20M and High Revenue estimate is $39.72M.
The Company currently has High Price Target of $4. The Low and Mean Price Targets are $3.5 and $3.75 respectively. These price targets are set after consensus analysis of 2 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month, 0 analysts have given this stock as Strong Buy where 0 issued Buy, 0 analysts think that it’s a Hold, 2 told Underperform and0 assigned Sell rating.